Novo Nordisk A/S (NVO)vsNovartis AG ADR (NVS)
NVO
Novo Nordisk A/S
$37.82
-2.70%
HEALTHCARE · Cap: $177.74B
NVS
Novartis AG ADR
$150.47
-0.50%
HEALTHCARE · Cap: $302.86B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 482% more annual revenue ($333.65B vs $57.36B). NVO leads profitability with a 33.9% profit margin vs 17.5%. NVS appears more attractively valued with a PEG of 3.81. NVO earns a higher WallStSmart Score of 59/100 (C).
NVO
Buy59
out of 100
Grade: C
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NVO.
Margin of Safety
-56.8%
Fair Value
$95.95
Current Price
$150.47
$54.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 52 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 40.1%
Generating 28.1B in free cash flow
Large-cap with strong market position
Mega-cap, among the largest globally
Strong operational efficiency at 34.0%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 15.8%
Premium valuation, high expectations priced in
4.7% revenue growth
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.9% and operating margin at 40.1%.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
NVO profiles as a mature stock while NVS is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.45 — expect wider price swings.
NVO is growing revenue faster at 5.6% — sustainability is the question.
NVO generates stronger free cash flow (28.1B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (59/100 vs 48/100), backed by strong 33.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?